Literature DB >> 16274763

Spatial aspects of combined modality radiotherapy.

Rachel K Bodey1, Phil M Evans, Glenn D Flux.   

Abstract

BACKGROUND AND
PURPOSE: A combined modality radiotherapy (CMRT) incorporates both external beam radiotherapy (EBT) and targeted radionuclide therapy (TRT) components. The spatial aspects of this combination were explored by utilising intensity modulated radiotherapy (IMRT) to provide a non-uniform EBT dose distribution. PATIENTS AND METHODS: Three methods of prescribing the required non-uniform distribution of EBT dose are described, based on both physical and biological criteria according to the distribution of TRT uptake. The results and consequences of these prescriptions are explored by application to three examples of patient data.
RESULTS: The planning procedure adopted allowed IMRT plans to be produced that met the prescription requirements. However, when the treatment was planned as a CMRT, compared with the use of EBT alone, more satisfactory target doses could be achieved with lower doses to normal tissues. The effects of errors in EBT delivery and in the functional data were found to cause a non-uniform prescription to tend towards the uniform case.
CONCLUSIONS: The methods and results are relevant for more general biological treatment planning, in which IMRT may be used to produce dose distributions prescribed according to tumour function. The effects of delivery and dose calculation errors can have a significant impact on how such treatments should be planned.

Entities:  

Mesh:

Year:  2005        PMID: 16274763     DOI: 10.1016/j.radonc.2005.10.006

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  1 in total

1.  Radiolabelled apoptotic probe may be a vehicle for a novel multimodality radionuclide tumour therapy.

Authors:  S Dizdarevic; R McCready; J F C Turner; M C Bagley; P Blower; P Schmid; G Flux; A Hall; I Ziv
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-25       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.